CD274 and non-small cell lung carcinoma: INSIGNA (NCT03793179), and further trials comparing immunotherapy with combination immuno-chemotherapy, will allow validation of these findings, and in-depth analysis of NSCLC subsets characterized by PD-L1 in the near future.